These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 37356235)

  • 1. Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus.
    Rastogi A; Weir MR
    J Diabetes Complications; 2023 Aug; 37(8):108515. PubMed ID: 37356235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB; Pergola P
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
    Mahmud HA; Palmer BF
    Cardiorenal Med; 2024; 14(1):191-201. PubMed ID: 38513618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
    Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
    Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiorenal benefits of finerenone: protecting kidney and heart.
    González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
    Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
    Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
    Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 33358451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.
    Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A
    Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slowing the Progression of Diabetic Kidney Disease.
    Blazek O; Bakris GL
    Cells; 2023 Jul; 12(15):. PubMed ID: 37566054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding Prescribing Practices and Patient Experiences with Renin Angiotensin System Inhibitors Use in Chronic Kidney Disease: A Qualitative Study.
    Arney J; Gregg LP; Wydermyer S; Herrera MA; Richardson PA; Matheny ME; Akeroyd JM; Gobbel GT; Hung A; Virani SS; Navaneethan SD
    Cardiorenal Med; 2024; 14(1):34-44. PubMed ID: 38151011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When should we start and stop ACEi/ARB in paediatric chronic kidney disease?
    Chan EY; Ma AL; Tullus K
    Pediatr Nephrol; 2021 Jul; 36(7):1751-1764. PubMed ID: 33057769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis from the EMPA-REG OUTCOME
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.